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We show that the interpretation of molecular epidemiological data for extensively drug-resistant tuberculosis (XDR-TB) is de-
pendent on the number of different markers used to define transmission. Using spoligotyping, IS6110DNA fingerprinting, and
DNA sequence data, we show that XDR-TB in South Africa (2006 to 2008) was predominantly driven by the acquisition of sec-
ond-line drug resistance.
Molecular epidemiological studies of Mycobacterium tubercu-losis have been instrumental in informing tuberculosis (TB)
control policy in low-incidence settings (1–6). However, the ac-
curacy of molecular epidemiological inferences depends on
whether the genetic data accurately reflect the epidemiology.
Within the context of the M. tuberculosis epidemic, clustering of
identical or near-identical genotypes has been assumed to reflect
transmission, while nonclustered (unique) genotypes are inferred
to reflect the reactivation of a previous infection or importation of
TB from another setting (7, 8). However, these assumptions do
not hold true when studying drug-resistant tuberculosis, as they
do not take into account the fact that drug resistance may evolve
independently in strains with identical genetic backgrounds.
When drug resistance patterns are ignored, the interpretation of
clustered drug-resistant strains would be that they occurred by
transmission, while when included in the algorithm, the interpre-
tation could be that drug resistance was acquired, provided the
mutations are different. Failure to recognize these interpretational
errors might incorrectly inform policy, thereby negatively impact-
ing TB control strategy.
In order to curb the drug resistance epidemic, it is essential to
gain insight into the underlying causes of drug resistance in dif-
ferent geographical locations. This is particularly relevant with
respect to the extensively drug-resistant TB (XDR-TB) epidemic,
which is now a global phenomenon and has been identified in 100
countries (9). A recent XDR-TB review showed that spoligotyping
and or mycobacterial interspersed repetitive-unit–variable-num-
ber tandem-repeat (MIRU-VNTR) genotyping and IS6110 DNA
fingerprinting have been used to describe the epidemiology of
XDR-TB cases in different settings (10). However, these studies
have not investigated the possibility of the concurrent evolution of
drug resistance within strains with identical genetic backgrounds.
In this study, we aimed to investigate how the inclusion of differ-
ent genetic information might influence the interpretation of the
epidemiology of XDR-TB. The first available XDR-TB isolates
from 118 of 127 cases (93%) diagnosed in the Western Cape Prov-
ince of South Africa during the study period of November 2006 to
October 2008, were included in the study. During the study pe-
riod, routine drug susceptibility testing (DST) was expanded to
include the second-line drugs ofloxacin and amikacin. This policy
was implemented in February 2007 and applied to all existing and
newly diagnosed multidrug-resistant TB (MDR-TB) patients.
Thus, many of the included cases were receiving MDR-TB treat-
ment at the time that XDR-TB was diagnosed. These isolates were
genotyped using the internationally standardized methods of spo-
ligotyping (11) and IS6110 DNA fingerprinting (12) (see Table S1
in the supplemental material). In addition, targeted DNA se-
quencing was done to identify mutations in the inhA promoter
and the katG, rpoB, embB, pncA, gyrA, and rrs genes known to
confer resistance to isoniazid, rifampin, ethambutol, pyrazin-
amide, ofloxacin, amikacin, kanamycin, and capreomycin (13).
Molecular epidemiological inferences were made using the geno-
typing data from either individual markers or various combina-
tions of the different markers. A cluster was defined when isolates
shared identical genotypes according to the markers included in
the analysis (Table 1). When the resistance-conferring mutations
were included, we assumed that the order in which resistance ac-
cumulated was isoniazid, rifampin, ethambutol, pyrazinamide,
and ofloxacin, followed by aminoglycosides.
From Table 1, it is evident that spoligotyping had the lowest
discriminatory index, identifying only 9 spoligotype patterns,
which were grouped into 3 clusters (95% clustering) and 6 unique
spoligotypes. The IS6110 DNA fingerprinting method identified
34 strain genotypes. Of these, 11 clusters (81% clustering) and 23
unique DNA fingerprints were identified. When the spoligotype
and DNA fingerprint data were combined, they did not signifi-
cantly alter the proportion of clustered isolates (spoligotyping and
IS6110DNA fingerprinting, 79%, versus IS6110DNA fingerprint-
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ing only, 81%; P  0.87). These clusters remained largely intact
when incorporating mutations conferring isoniazid and rifampin
resistance (spoligotyping and IS6110 DNA fingerprinting with
isoniazid and rifampin resistance-conferring mutations, 71%,
versus spoligotyping and IS6110 DNA fingerprinting only, 79%; P
 0.23). Epidemiologic support for transmission MDR-TB was
not shown, as MDR-TB cases that did not progress to XDR-TB
were excluded from the study, thereby preventing the identifica-
tion of contacts. The inclusion of mutations conferring pyrazin-
amide and ethambutol resistance reduced the proportion of clus-
tering to 58% (P 0.031). This suggests that circulating MDR-TB
strains have independently acquired ethambutol and pyrazin-
TABLE 2 Clustering of atypical Beijing XDR-TB strains using a combination of different genetic markers
Genetic marker(s)
Strict clustering of IS6110 Relaxed clustering of IS6110
No. of unique
genotypes
No. of
clustered
genotypes
No. of
clusters % clustering
No. of unique
genotypes
No. of clustered
genotypes
No. of
clusters % clustering
Spoligotyping 0 62 1 100.0 0 62 1 100.0
IS6110 DNA fingerprinting 7 55 3 88.7 2 60 1 96.8
Spoligotyping IS6110 7 55 3 88.7 2 60 1 96.8
Spoligotyping IS6110 katG 7 55 4 88.7 2 60 2 96.8
Spoligotyping IS6110 inhAP 9 53 4 85.5 2 60 3 96.8
Spoligotyping IS6110 rpoB 9 53 4 85.5 3 59 2 95.2
Spoligotyping IS6110 katG inhAP 9 53 5 85.5 2 60 4 96.8
Spoligotyping IS6110 katG inhAP
rpoB
10 52 5 83.9 3 59 4 95.2
Spoligotyping IS6110 katG inhAP
rpoB pncA
13 49 5 79.0 8 54 3 87.1
Spoligotyping IS6110 katG inhAP
rpoB embB
10 52 6 83.9 3 59 5 95.2
Spoligotyping IS6110 katG inhAP
rpoB pncA embB
13 49 6 79.0 8 54 4 87.1
Spoligotyping IS6110 katG inhAP
rpoB pncA embB gyrA
30 32 6 51.6 19 43 8 69.4
Spoligotyping IS6110 katG inhAP
rpoB pncA embB rrs
14 48 6 77.4 9 53 4 85.5
Spoligotyping IS6110 katG inhAP
rpoB pncA embB gyrA rrs
31 31 6 50.0 20 42 8 67.7
TABLE 1 Clustering of all XDR-TB strains using a combination of different genetic markers
Genetic marker(s)
Strict clustering of IS6110 Relaxed clustering of IS6110
No. of unique
genotypes
No. of
clustered
genotypes
No. of
clusters % clustering
No. of unique
genotypes
No. of
clustered
genotypes
No. of
clusters % clustering
Spoligotyping 6 112 3 94.9 6 112 3 94.9
IS6110 DNA fingerprinting 23 95 11 80.5 11 107 4 90.7
Spoligotyping IS6110 25 93 12 78.8 13 105 5 89
Spoligotyping IS6110 katG 29 89 13 75.4 17 101 6 85.6
Spoligotyping IS6110 inhAP 29 89 14 75.4 15 103 8 87.3
Spoligotyping IS6110 rpoB 28 90 13 76.3 15 103 6 87.3
Spoligotyping IS6110 katG inhAP 32 86 15 72.9 18 100 9 84.7
Spoligotyping IS6110 katG inhAP
rpoB
34 84 15 71.2 20 98 9 83.1
Spoligotyping IS6110 katG inhAP
rpoB pncA
46 72 14 61 32 86 11 72.9
Spoligotyping IS6110 katG inhAP
rpoB embB
36 82 16 69.5 20 98 11 83.1
Spoligotyping IS6110 katG inhAP
rpoB pncA embB
50 68 13 57.6 33 85 13 72
Spoligotyping IS6110 katG inhAP
rpoB pncA embB gyrA
76 42 10 35.6 62 56 13 47.5
Spoligotyping IS6110 katG inhAP
rpoB pncA embB rrs
55 63 12 53.4 39 79 12 66.9
Spoligotyping IS6110 katG inhAP
rpoB pncA embB gyrA rrs
79 39 10 33.1 65 53 13 44.9
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amide resistance and were then subsequently transmitted, as dem-
onstrated by the estimated proportion of clustering (58%). When
mutations conferring second-line resistance were incorporated
into the clustering algorithm, a significant decrease in the propor-
tion of clustered isolates was observed (33% with versus 58%
without; P  0.000235). This suggests that resistance to fluoro-
quinolones and aminoglycosides was subsequently acquired in
MDR-TB strains that were already resistant to ethambutol and
pyrazinamide. The absence of transmission was supported by an
analysis of the clinic location where each patient reported, as only
10 patients (within strictly defined clusters) or 15 patients (within
relaxed clusters) were from the same community (see Table S1 in
the supplemental material).
A comparison of the IS6110 patterns with previously reported
studies (13, 14) showed that 53% of the patients were infected with
atypical Beijing XDR-TB strains, which were genotypically closely
related to those reported in the Eastern Cape Province of South
Africa. Clustering of the atypical Beijing strains was found to be
significantly higher than that for the rest of the strain population
(50% versus 14% without clustering; P 0.000036) (Tables 2 and
3). This finding was based on the analysis of a combination of all of
the markers; therefore, it is unlikely that clustering is a function of
genetic stability (15) rather than transmission. These strains were
genotypically identical to the atypical Beijing XDR-TB strains
identified in the neighboring Eastern Cape Province (13), suggest-
ing importation via migration (16). Analysis of the residential
location of these cases showed that 10 patients were grouped
within 2 suburbs, suggesting that these strains are now being
transmitted within urban settings in the Western Cape Province.
We acknowledge that the proportion of clustered cases may be
underestimated, as patients with XDR-TB may have died before
diagnosis, patient isolates were not tested for second-line resis-
tance, patient isolates were not available for genotyping, or diag-
nostic data were not available. Furthermore, our definition of an
IS6110 DNA fingerprint cluster may have been too stringent (17,
18). By relaxing the definition of a cluster to allow for 2 IS6110
band variations, we identified 13 clusters and 65 unique cases,
which increased the proportion of clustered cases to 45% (atypical
Beijing, 68%, versus other, 20%). We also acknowledge that our
analysis may have led to an overestimate of clustering, as the same
mutation may be acquired independently in different isolates.
From the abovementioned results, it is evident that in this
high-incidence setting, the estimate of the proportion of clustered
cases is sensitive to the genotyping methods used. This cautions
the use of a single genotyping method to describe the epidemiol-
ogy of XDR-TB. Accordingly, we propose the inclusion of muta-
tional data together with an informative genotyping method
(IS6110 DNA fingerprinting or MIRU-VNTR typing) to accu-
rately reflect the epidemiology of XDR-TB.
Our genotyping results are in line with previous reports, which
concluded that XDR-TB is acquired following the transmission of
MDR-TB strains in the Western Cape Province of South Africa
(19). Furthermore, we show that the XDR-TB epidemic in this
region is strongly influenced by migration from the Eastern Cape
(16), a region where an outbreak of an atypical Beijing XDR-TB
strain has been reported (13). Given that the outcome of XDR-TB
treatment is dismal in this region (20), it is essential that rapid
drug susceptibility tests are implemented to guide the formulation
of a strengthened MDR-TB treatment regimen to prevent the ac-
quisition of additional resistance.
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TABLE 3 Clustering of XDR-TB strains other than atypical Beijing strains using a combination of different genetic markers
Genetic marker(s)
Strict clustering of IS6110 Relaxed clustering of IS6110
No. of unique
genotypes
No. of
clustered
genotypes
No. of
clusters % clustering
No. of unique
genotypes
No. of
clustered
genotypes
No. of
clusters % clustering
Spoligotyping 6 50 3 89.3 6 50 3 89.3
IS6110 DNA fingerprinting 16 40 8 71.4 9 47 3 83.9
Spoligotyping IS6110 18 38 9 67.9 11 45 4 80.4
Spoligotyping IS6110 katG 22 34 9 60.7 15 41 4 73.2
Spoligotyping IS6110 inhAP 20 36 10 64.3 13 43 5 76.8
Spoligotyping IS6110 rpoB 19 37 9 66.1 12 44 4 78.6
Spoligotyping IS6110 katG inhAP 23 33 10 58.9 16 40 5 71.4
Spoligotyping IS6110 katG inhAP
rpoB
24 32 10 57.1 17 39 5 69.6
Spoligotyping IS6110 katG inhAP
rpoB pncA
33 23 9 41.1 24 32 8 57.1
Spoligotyping IS6110 katG inhAP
rpoB embB
26 30 10 53.6 17 39 6 69.6
Spoligotyping IS6110 katG inhAP
rpoB pncA embB
37 19 7 33.9 25 31 9 55.4
Spoligotyping IS6110 katG inhAP
rpoB pncA embB gyrA
46 10 4 17.9 43 13 5 23.2
Spoligotyping IS6110 katG inhAP
rpoB pncA embB rrs
41 15 6 26.8 30 26 8 46.4
Spoligotyping IS6110 katG inhAP
rpoB pncA embB gyrA rrs
48 8 4 14.3 45 11 5 19.6
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